Core Viewpoint - Puyuan Precision Electric Technology Co., Ltd. is facing scrutiny regarding its necessity for fundraising through a Hong Kong listing, especially given its recent performance and high expenses despite holding significant cash reserves [2][5]. Shareholder Lock-up Release - On October 9, Puyuan Precision announced the release of lock-up shares totaling approximately 118 million shares, representing 61.01% of the company's total equity, held by six shareholders [3]. - The company went public on the Sci-Tech Innovation Board in 2022, with a total share capital of approximately 121 million shares, of which 96 million shares were subject to lock-up [3]. Financial Performance - In the first half of the year, Puyuan Precision reported total revenue of approximately 355 million yuan, a year-on-year increase of 15.57%, while total costs rose to 375 million yuan, reflecting a growth of about 12.0% [5]. - The company experienced a net profit of -11 million yuan after deducting non-recurring items, marking a year-on-year increase of 42.32% in losses [5]. Expense Analysis - The company's profit was significantly impacted by high expenses rather than operating costs, with total expenses reaching 211 million yuan, which exceeded operating costs of 158 million yuan [6]. - The breakdown of expenses includes sales expenses of 58 million yuan (up 6.46%), management expenses of 50 million yuan (up 5.32%), and R&D expenses of 108 million yuan (up 23.22%) [6]. Asset and Liability Overview - As of the first half of the year, Puyuan Precision's total assets amounted to 3.794 billion yuan, with current assets of 2.592 billion yuan and non-current assets of 1.201 billion yuan [6]. - The company reported total liabilities of 680 million yuan and equity of 3.113 billion yuan, resulting in an asset-liability ratio of only 17.93% [6]. Cash Flow Insights - The company recorded a total cash inflow from investment activities of 393 million yuan, primarily from recovering investments, while cash outflows totaled 463 million yuan [7]. - The net cash flow from investment activities was -70 million yuan, indicating a negative cash flow situation [7].

Summary of Key Points Core Viewpoint The Hong Kong Stock Exchange (HKEX) has seen significant activity in new listings and IPO applications, with notable performances from newly listed companies and ongoing interest from various sectors. Group 1: New Listings - On October 10, HKEX had two companies listed: ZhiDa Technology and JinYe International Group, with ZhiDa Technology closing up 192.14% at HKD 195.50 per share, giving it a market capitalization of approximately HKD 11.7 billion [3] - JinYe International Group saw a remarkable first-day increase of 330.00%, closing at HKD 2.15 per share, with a total market value of around HKD 860 million [3] Group 2: Ongoing IPO Applications - As of October 10, there are three companies currently undergoing the IPO process, with one completing its offering on the same day [4] - The companies include XuanZhu Bio-B, YunJi, and HaiXi New Drug, focusing on biopharmaceuticals and AI-enabled robotics [4] Group 3: Recent IPO Applications - From September 29 to October 10, a total of 35 companies submitted applications for listing on the main board of HKEX [8] - Notable applicants include: - LanNa Cheng, a clinical-stage biotech company focused on radiopharmaceuticals for cancer treatment [15] - JiMi Technology, a leading global brand in the projection industry [17] - WeiYi Holdings, a top player in China's digital health services market [21] - PuYuan Precision, the largest electronic measurement instrument supplier in China [23] - HuanChuang Technology, a leader in high-precision spatial perception solutions [26] - JingCun Technology, an independent manufacturer of embedded storage products [28] - MaiKeAoTe, a platform biotech company with core products in clinical trials [31] - JingShi Measurement and Control, focusing on flexible manufacturing solutions [33] - LuoShi Robotics, dedicated to the design and commercialization of intelligent robots [35] - ChangChun High-tech, a major player in the Chinese pharmaceutical industry [37] - JuXin Microelectronics, specializing in intelligent sensing and machine vision solutions [40] - BeiDa Pharmaceutical, a successful biopharmaceutical company in China [42] - LiOu Group, focusing on AI-driven digital marketing and smart systems [45] - Natural Hall, the third-largest domestic cosmetics group in China [47] - MiLian Technology, an online emotional social platform [50] - JingHe Integration, a global 12-inch pure wafer foundry [52] Group 4: Financial Performance - ZhiDa Technology's total market capitalization reached approximately HKD 11.7 billion on its first day [3] - JinYe International Group's market value was around HKD 860 million after its debut [3] - Financial data for various companies applying for IPOs indicates a mix of revenues and losses, with some companies like WeiYi Holdings projecting significant revenue growth from HKD 13.68 billion in 2022 to HKD 54.96 billion in 2024 [21] - Other companies like JingCun Technology expect revenue growth from HKD 20.96 billion in 2022 to HKD 37.14 billion in 2024 [28] Group 5: Risk Factors - Companies have disclosed various risk factors in their IPO applications, including reliance on successful drug approvals, competition, and market demand fluctuations [16][19][22][24][27][36][41][43][46]